Delivery Order SPE2DB20D2104-SPE2DB25FNAVN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Clindamycin Phosphate 1% Foam 100GM with a ceiling value of $1,744.22. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by October 23, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Clindamycin Phosphate 1% Foam in 50-gram units, with a ceiling value of $11,750.50. This is a firm fixed-price delivery order with no set-aside designation, indicating the contract was competitively awarded. The ultimate completion date is September 8, 2025, and the product will be sourced from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Clindamycin Phosphate 1% Foam (100 grams) with a ceiling value of $1,553.04. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Clindamycin Phosphate 1% Foam in 100-gram units, with a ceiling value of $1,208.38. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Clindamycin Phosphate 1% Foam in 50-gram units, valued at $1,315.27. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 8, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its principal...
- The Defense Logistics Agency awarded a delivery order valued at $25,629.43 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam 100GM on September 15, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to the pharmaceutical distributor. The products will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 16, 2025. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $6,252.08 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. The contract, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, served as the prime contractor, with performance of work also...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM with a ceiling value of $4,383.79 under a firm fixed-price contract structure. This delivery order, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive award supporting federal medical procurement needs. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,072.56 to AmerisourceBergen Drug Corp for Clindamycin Phosphate 1% Foam 50GM, a topical antibiotic pharmaceutical product. This competitive, non-set-aside contract award was executed on August 7, 2025, with an ultimate completion date of August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract operates under a firm fixed-price delivery order structure,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,347.82 to AmerisourceBergen Drug Corp for the supply of Clindamycin Phosphate 1% Foam in 100GM units. This award, issued on August 21, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNAVNDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Clindamycin Phosphate 1% Foam in 50-gram units. This is a firm fixed price contract with a ceiling value of $1,806.94 and an ultimate completion date of September 19, 2025. The award was made without a set-aside designation through competitive procurement, with performance to occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company maintains an extensive portfolio of federal contract awards covering a broad spectrum of pharmaceutical products and medical supplies, from diabetes medications to specialty treatments and vaccines. This delivery order for Clindamycin Phosphate, an antibiotic foam used for topical treatment, represents one of numerous small-to-medium value transactions the company fulfills under its prime IDC vehicle, demonstrating its capability to meet diverse federal healthcare supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/18/25 |